IN SILICO CHARACTERIZATION, MOLECULAR DOCKING, AND IN VITRO EVALUATION OF TRIAZOLE DERIVATIVES AS POTENTIAL ANTICANCER AGENTS
Objective: The objective of the study was to perform in silico molecular docking and in vitro anticancer studies of proposed 1,2,4-triazole derivatives for the determination of their anticancer activity.
Methods: A series of 10 triazole compounds with different substituents were drawn in ACD Lab ChemSketch software. Molecular and biological properties were identified using Molinspiration software. The compounds that obeyed Lipinski rule of five are subjected for pharmacokinetic parameters prediction and docking analysis. SwissDock ADME software is used for the prediction of absorption, distribution, metabolism, and elimination. Then, the compounds are docked with target enzymes in Chimera software 1.14 version. The molecular docking studies revealed favorable molecular interactions and binding energies. The compounds that showed good docking results were synthesized through wet lab synthesis and further preceded for in vitro anticancer studies.
Results: Three compounds are selected for wet lab synthesis due to their good docking results compared to other compounds. The synthesized compounds are subjected to different in vitro anticancer studies and found to be having potential anticancer activity.
Conclusion: The pharmacokinetic and docking studies conclude that the triazole compounds have potential as anticancer agents. The in vitro anticancer studies revealed that the triazole derivatives are having high potency of anticancer activity against pancreatic cell lines.
2. Xu Z, Zhao SJ, Liu Y. 1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships. Eur J Med Chem 2019;183:111700.
3. Haider S, Alhusban M, Chaurasiya ND, Tekwani BL. Isoform selectivity of harmine-conjugated 1,2,3-triazoles against human monoamine oxidase. Future Med Chem 2018;10:1435-48.
4. Scott AT, Weitz M, Breheny PJ, Ear PH, Darbro B, Brown BJ, et al. Gene expression signatures identify novel therapeutics for metastatic pancreatic neuroendocrine tumors. Clin Cancer Res 2020;26:2011-21.
5. Lewis CS, Thomas HE, Orr-Asman MA, Green LC, Boody RE, Matiash K, et al. mTOR kinase inhibition reduces tissue factor expression and growth of pancreatic neuroendocrine tumors. J Thromb Haemost 2019;17:169-82.
6. Rawla P, Sunkara T, Gaduputi V. Epidemiology of pancreatic cancer: Global trends, etiology and risk factors. World J Oncol 2019;10:10-27.
7. Lee JI, Kil JH, Yu GH, Karadeniz F, Oh JH, Seo Y, et al. 3,5-Dicaffeoyl-epi-quinic acid inhibits the PMA-stimulated activation and expression of MMP-9 but not MMP-2 via downregulation of MAPK pathway. Z Naturforsch C J Biosci 2020;75:113-20.
8. Ugurel S, Röhmel J, Ascierto PA, Becker JC, Flaherty KT, Grob JJ, et al. Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition. Eur J Cancer 2020;130:126-38.
9. Wang X, Xie J, Proud CG. Eukaryotic elongation factor 2 kinase (eEF2K) in cancer. Cancers (Basel) 2017;9:162.
10. Inokuchi K, Nakayama K, Tauchi T, Takaku T, Yokose N, Yamaguchi H, et al. Therapeutic effects of tyrosine kinase inhibitors and subtypes of BCR-ABL1 transcripts in Japanese chronic myeloid leukemia patients with three-way chromosomal translocations. Leuk Res 2018;65:74-9.
11. Calderwood SK. HSF1, a versatile factor in tumorogenesis. Curr Mol Med 2012;12:1102-7.
12. Shomali N, Hatamnezhad LS, Tarzi S, Tamjidifar R, Xu H, Shotorbani SS. Heat shock proteins regulating toll-like receptors and the immune system could be a novel therapeutic target for melanoma. Curr Mol Med 2020;13:3432.
13. Gasic I, Groendyke BJ, Nowak RP, Yuan JC, Kalabathula J, Fischer ES, et al. Tubulin resists degradation by cereblon-recruiting PROTACs. Cells 2020;9:E1083.
14. Lu Y, Chen J, Xiao M, Li W, Miller DD. An overview of tubulin inhibitors that interact with the colchicine binding site. Pharm Res 2012;29:2943-71.
15. Yamamoto KN, Nakamura A, Liu LL, Stein S, Tramontano AC, Inoue Y, et al. Computational modeling of pancreatic cancer patients receiving FOLFIRINOX and gemcitabine-based therapies identifies optimum intervention strategies. PLoS One 2019;14:e0215409.
16. Chien ST, Kumar A, Pandey S, Yen CK, Wang SY, Wen ZH, et al. Cancer biology aspects of computational methods and applications in drug discovery. Curr Pharm Des 2018;24:3758-66.
17. Hochscherf J, Lindenblatt D, Steinkrüger M, Yoo E, Ulucan Ö, Herzig S, et al. Development of a high-throughput screening-compatible assay to identify inhibitors of the CK2?/CK2? interaction. Anal Biochem 2015;468:4-14.
18. Popescu T, Lupu AR, Raditoiu V, Purcar V, Teodorescu VS. On the photocatalytic reduction of MTT tetrazolium salt on the surface of TiO2 nanoparticles: Formazan production kinetics and mechanism. J Colloid Interface Sci 2015;457:108-20.
19. Stockert JC, Horobin RW, Colombo LL, Blázquez-Castro A. Tetrazolium salts and formazan products in cell biology: Viability assessment, fluorescence imaging, and labeling perspectives. Acta Histochem 2018;120:159-67.
20. Rai Y, Pathak R, Kumari N, Sah DK, Pandey S, Kalra N, et al. Mitochondrial biogenesis and metabolic hyperactivation limits the application of MTT assay in the estimation of radiation induced growth inhibition. Sci Rep 2018;8:1531.
21. Stockert JC, Horobin RW, Colombo LL, Blázquez-Castro A. Tetrazolium salts and formazan products in cell biology: Viability assessment, fluorescence imaging, and labeling perspectives. Acta Histochem 2018;120:159-67.
22. Chen X, Li H, Tian L, Li Q, Luo J, Zhang Y. Analysis of the physicochemical properties of acaricides based on lipinski’s rule of five. J Comput Biol 2020;34:2316.
23. Pandey AK, Siddiqui MH, Dutta R. Drug-likeness prediction of designed analogues of isoniazid standard targeting FabI enzyme regulation from P. falciparum. 2019;15:364-8.
24. Ishida S. Adme 1Organs-on-a-chip: Current applications and consideration points for in vitro ADME-Tox studies. Drug Metab Pharmacokinet 2018;33:49-54.
25. Yan G, Wang X, Chen Z, Wu X, Pan J, Huang Y, et al. In-silico ADME studies for new drug discovery: From chemical compounds to Chinese herbal medicines. Curr Drug Metab 2017;18:535-9.
26. Liu CF, Shen QK, Li JJ. Synthesis and biological evaluation of novel 7-hydroxy-4-phenylchromen-2-one-linked to triazole moieties as potent cytotoxic agents. Curr Drug Metab 2017;18:535-9.
27. Farooq S, Hussain A, Qurishi MA, Hamid A, Koul S. Synthesis and biological evaluation of novel 7-hydroxy-4-phenylchromen-2-one-linked to triazole moieties as potent cytotoxic agents. J Enzyme Inhib Med Chem 2017;32:1111-9.
28. Madadi NR, Penthala NR. Synthesis and biological evaluation of novel 4,5-disubstituted 2H-1,2,3-triazoles as cis-constrained analogues of combretastatin A-4. Eur J Med Chem 2015;103:123-32.
29. Al-Omair MA, Sayed AR, Youssef MM. Synthesis of novel triazoles, tetrazine, thiadiazoles and their biological activities. Molecules 2015;20:2591-10.
30. Tim E, Desaulniers JP. Chemical architecture and applications of nucleic acid derivatives containing 1,2,3-triazole functionalities synthesized via click chemistry. Molecules 2012;17:12665-703.
31. Onder FC, Durdagi S, Sahin K, Ozpolat B, Ay M. Design, synthesis, and molecular modeling studies of novel coumarin carboxamide derivatives as eEF-2K inhibitors. J Chem Inf Model 2020;60:L1766-78.
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.